Related Experiment Video
Updated: Jun 9, 2026

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
[Levofloxacin in children]
1Comité de Lutte contre les Infections Nosocomiales, Centre Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil. emmanuel.grimprel@trs.aphp.fr
Insights
Levofloxacin shows promise for treating resistant infections in children, including acute otitis media and pneumonia. Further pediatric studies are needed to confirm its efficacy and safety for wider European use.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Abstract:
Levofloxacin (levogyre form of ofloxacin) has been approved for the treatment of acute and chronic sinusitis, pneumonia, and exacerbation of bronchopulmonary diseases, urinary, digestive and biliary infections in adults. Its pharmacokinetic properties and microbiological spectrum, including penicillin non-susceptible Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Mycoplasma pneumoniae, suggest a potential interest in drug-resistant acute otitis media and community-acquired pneumonia. Only few studies have been performed in the paediatric population but they provided encouraging efficacy and safety data. Complementary data are needed before considering its use in Europe in the setting of a paediatric investigation plan.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
